<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Current status of the clinical trials of vaccines and candidate therapy for cytokine release syndrome (CRS) against SARS-CoV-2 infection (Source: National Institute of Health, 
   <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/</ext-link>) Accessed on Aug 1, 2020
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Company</th>
    <th>Approach</th>
    <th>Stage</th>
    <th>Strategy</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Arcturus Therapeutics</td>
    <td>Vaccine</td>
    <td>Phase 1/2</td>
    <td>Engineering RNA with nanoparticle</td>
   </tr>
   <tr>
    <td>BioNTech</td>
    <td>Vaccine</td>
    <td>Phase 3</td>
    <td>mRNA</td>
   </tr>
   <tr>
    <td>Zydus Cadila</td>
    <td>ZyCoV-D vaccine</td>
    <td>Phase 1/2</td>
    <td>RNA recombinant measles virus</td>
   </tr>
   <tr>
    <td>Mudoch Childre’s Research Institute</td>
    <td>BCG vaccine</td>
    <td>Phase 2/3</td>
    <td>Live attenuated virus</td>
   </tr>
   <tr>
    <td>Medicago, GSK, Dynavax</td>
    <td>Plant-based vaccine</td>
    <td>Phase 1</td>
    <td>Virus-like particle</td>
   </tr>
   <tr>
    <td>CureVac</td>
    <td>Vaccine</td>
    <td>Phase 1</td>
    <td>Man-made mRNA</td>
   </tr>
   <tr>
    <td>Eli Lilly</td>
    <td>Treatment</td>
    <td>Phase 3</td>
    <td>Antibody treatment</td>
   </tr>
   <tr>
    <td>GlaxoSmithkline+ Clover Biopharmaceuticals</td>
    <td>Vaccine</td>
    <td>Phase 1</td>
    <td>Engineering adjuvants with proteins</td>
   </tr>
   <tr>
    <td>Inovio Pharmaceuticals</td>
    <td>Vaccine</td>
    <td>Phase 1</td>
    <td>DNA vaccine</td>
   </tr>
   <tr>
    <td>Johnson &amp; Johnson</td>
    <td>Vaccine and treatment</td>
    <td>Phase 1/2</td>
    <td>Deactivated virus</td>
   </tr>
   <tr>
    <td>Pfizer-BioNTech</td>
    <td>Vaccine and treatment</td>
    <td>Phase 2/3</td>
    <td>
     <p>Has not yet revealed strategy, five-point plan released</p>
     <p>RNA vaccine</p>
    </td>
   </tr>
   <tr>
    <td>Regeneron Pharmaceuticals</td>
    <td>Treatment</td>
    <td>Phase 3</td>
    <td>Cocktail of antibodies</td>
   </tr>
   <tr>
    <td>Sanofi</td>
    <td>Vaccine and treatment</td>
    <td>Phase 3</td>
    <td>Chimera of RNA viruses, Kevzara drug</td>
   </tr>
   <tr>
    <td>Takeda</td>
    <td>Treatment</td>
    <td>Treatment phase</td>
    <td>Plasma of treated patients</td>
   </tr>
   <tr>
    <td>Vir Biotechnology</td>
    <td>Treatment</td>
    <td>Phase 1</td>
    <td>Viral replication inhibitor</td>
   </tr>
   <tr>
    <td>Ascletis Pharma</td>
    <td>Treatment</td>
    <td>Phase 1b</td>
    <td>Cocktail of danoprevir and titonavir</td>
   </tr>
   <tr>
    <td>Gamaleya Institute of Epidemiology and Microbiology</td>
    <td>Vaccine</td>
    <td>Phase 2</td>
    <td>Isolated strain</td>
   </tr>
   <tr>
    <td>Siberian Vector Institute</td>
    <td>Vaccine</td>
    <td>Phase 1</td>
    <td>Using a platform first developed for Ebola</td>
   </tr>
   <tr>
    <td>Moderna Therapeutics</td>
    <td>Vaccine</td>
    <td>Phase 3</td>
    <td>RNA vaccine (mRNA −1273)</td>
   </tr>
   <tr>
    <td>CanSino Biologics</td>
    <td>Vaccine</td>
    <td>To start phase 3</td>
    <td>
     <p>SARS-CoV-2 genetic code entwined in harmless virus</p>
     <p>Non-replicating virus</p>
    </td>
   </tr>
   <tr>
    <td>Gilead Sciences</td>
    <td>Treatment</td>
    <td>Phase 3</td>
    <td>Remdesivir</td>
   </tr>
   <tr>
    <td>Oxford University</td>
    <td>Vaccine</td>
    <td>Phase 2/3 trial in UK, phase 3 trials in SA and Brazil</td>
    <td>
     <p>AZD 1222</p>
     <p>Non-replicating virus</p>
    </td>
   </tr>
   <tr>
    <td>Bharat Biotech</td>
    <td>Vaccine</td>
    <td>Phase 1/2</td>
    <td>COVAXIN inactivated virus</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
